| We have working groups with the Directorate-General for Public Health, the Directorate-General for Mental Health and Addictions, and the Directorate-General for Pharmacy of the Generalitat Valenciana [Valencia Regional Government]. | HIV
> HIV | 监管合作伙伴关系
> 与监管机构合作 | 5,000 | Local | Regularly | 119026705868 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | 患者权益倡导
> 患者权利 | 监管合作伙伴关系
> 与监管机构合作 | 10,000 | National | Sometimes | 119073823192 |
| IPTs [Informes de Posicionamiento Terapéutico – Therapeutic Positioning Reports], meetings with the Ministry, and so forth. | 呼吸系统
> 肺纤维化 | 监管合作伙伴关系
> 与监管机构合作 | 1,000 | National | Regularly | 119075356350 |
| IPT [Informe de Posicionamiento Terapéutico – Therapeutic Positioning Report]. | 神经肌肉
> 杜氏 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 5,000 | National | Regularly | 119045011464 |
| We participate in Health Technology Assessments for certain medicines. | 患者权益倡导
> 患者权利 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | We do not communicate with patients directly | National | Rarely | 119049693177 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | 患者权益倡导
> 患者权利 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 10,000 | National | Sometimes | 119073823192 |
| We have recently completed IPT [Informe de Posicionamiento Terapéutico – Therapeutic Positioning Report] assessments for Anifrolumab [for adults with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE)] and Voclosporin [used to treat lupus nephritis].We are currently engaged in the IPT process for Obinutuzumab [used to treat specific blood cancers and active lupus nephritis]. | 风湿性
> 狼疮 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100,000 | National | Regularly | 119076492282 |
| We are engaged with the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency of Medicines and Medical Devices] to advocate for access to innovative treatments. | 患者权益倡导
> 患者权利 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | We do not communicate with patients directly | National | Regularly | 119012238994 |
| Community of Madrid, Department of Education, Department of Health. | 出血
> 出血性疾病：大多数类型 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 5,000 | Regional | Regularly | 119012535987 |
| We provide advisory input to government authorities on specific matters and regulatory provisions relating to our area of practice — the older adult population. | 老年人
> 老年人 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | We do not communicate with patients directly | National | Regularly | 119013803044 |
| Meetings with the Directorate-General for the Common Benefits Package and Pharmacy. | 稀有
> 罕见病：代谢/溶酶体 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 100 | National | Rarely | 119022231157 |
| We actively participate in meetings with the Ministry of Health, including with the HIV Control Division — covering viral hepatitis, tuberculosis, and other STIs [ITS, Infecciones de Transmisión Sexual – Sexually Transmitted Infections] — as well as with the Directorate-General for Pharmacy, among others. | HIV
> HIV | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 100,000 | National | Regularly | 119036696548 |
| New therapeutic targets and State Health Council. | 风湿性
> 风湿性疾病：大多数类型 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 10,000 | National | Regularly | 119062924366 |
| Ministry of Health. | 心血管
> 心血管和心脏疾病 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 5,000 | National | Sometimes | 119072934071 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | 患者权益倡导
> 患者权利 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 10,000 | National | Sometimes | 119073823192 |
| IPTs [Informes de Posicionamiento Terapéutico – Therapeutic Positioning Reports], meetings with the Ministry, and so forth. | 呼吸系统
> 肺纤维化 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 1,000 | National | Regularly | 119075356350 |
| Not in my capacity as President of ACPA [Asociación Canaria de Pacientes - Canary Islands Patients’ Association], but rather as a member of the POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] Patient Platform and as President of Feasam [Federación de Asociaciones de Salud Mental de la Región de Murcia - Federation of Mental Health Associations of the Region of Murcia]. | 心血管
> 心血管和心脏疾病 | 监管合作伙伴关系
> 与其他医疗保健倡导者 | 100 | National | No | 119053738286 |
| Through ACCU [Asociaciones de Crohn y Colitis Ulcerosa - Crohn’s and Ulcerative Colitis Associations] Spain. | 胃肠道
> 胃肠道：其他 | 监管合作伙伴关系
> 与其他医疗保健倡导者 | 1,000 | Regional | Sometimes | 119053970542 |
| FEDER [Federación Española de Enfermedades Raras – Spanish Federation of Rare Diseases] and EURORDIS [European Rare Disease Organisation]. | 稀有
> 威尔逊病 | 监管合作伙伴关系
> 与其他医疗保健倡导者 | 100 | National | Regularly | 119078667611 |
| Legislation pertaining to patients living with a rare disease. | 稀有
> 罕见病：遗传性 | 影响政策和立法
> 影响医疗保健政策和立法 | 1,000 | National | Regularly | 119012112198 |
| Legal, policy, institutional, and corporate actions. | 患者安全
> 医源性 | 影响政策和立法
> 影响医疗保健政策和立法 | 1,000 | National | Regularly | 119045262726 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill [Proposición de Ley] and two Non-Legislative Motions [Proposiciones No de Ley] in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | 胃肠道
> 乳糜泻 | 影响政策和立法
> 影响医疗保健政策和立法 | 100,000 | National | Regularly | 119053766557 |
| Letters were submitted to the Ministry of Health. | 稀有
> 罕见病：遗传性 | 影响政策和立法
> 影响医疗保健政策和立法 | 100 | National | Regularly | 119065350505 |
| In our country [Spain] it is challenging, but we do have channels through which we are able to communicate. | 肝脏
> 肝脏疾病：移植 | 影响政策和立法
> 影响医疗保健政策和立法 | 5,000 | National | Rarely | 119069515067 |
| IPTs [Informes de Posicionamiento Terapéutico – Therapeutic Positioning Reports], meetings with the Ministry, and so forth. | 呼吸系统
> 肺纤维化 | 影响政策和立法
> 影响医疗保健政策和立法 | 1,000 | National | Regularly | 119075356350 |
| Ongoing contact and coordination with César Hernández [Director General of the Common Portfolio of the NHS and Pharmacy within the Spanish Ministry of Health]. | 稀有
> 罕见病：大多数类型 | 影响政策和立法
> 影响医疗保健政策和立法 | 100,000 | National | Regularly | 119078056907 |
| In the Community of Madrid, we are consulted on medicines and their importance for our patient community. | 出血
> 出血性疾病：大多数类型 | 影响政策和立法
> 参与公众听证会和咨询 | 5,000 | Regional | Regularly | 119036712634 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | 慢性
> 慢性病（总体） | 影响政策和立法
> 参与公众听证会和咨询 | We do not communicate with patients directly | National | Regularly | 119052165521 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill [Proposición de Ley] and two Non-Legislative Motions [Proposiciones No de Ley] in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | 胃肠道
> 乳糜泻 | 影响政策和立法
> 参与公众听证会和咨询 | 100,000 | National | Regularly | 119053766557 |
| We do not intervene in pricing decisions; however, we advocate for patient and stakeholder interests before the relevant public authorities. | 神经系统
> 多发性硬化症 | 影响政策和立法
> 参与公众听证会和咨询 | 5,000 | Local | Regularly | 119064523376 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill (Proposición de Ley) and two Non-Legislative Motions (Proposiciones No de Ley) in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | 胃肠道
> 乳糜泻 | 影响政策和立法
> 动员议员和政治领导人 | 100,000 | National | Regularly | 119053766557 |
| We are registered as an interest group with the Generalitat Valenciana in the REGIA [Registro de Grupos de Interés de la Administración de la Generalitat - Register of Interest Groups of the Administration of the Generalitat Valenciana] register under number 188. We participate on a bimonthly basis in strategic meetings held with both the Regional Ministry of Health and the Regional Ministry of Equality and Social Services. | HIV
> HIV | 影响政策和立法
> 动员议员和政治领导人 | 5,000 | Local | Regularly | 119072832940 |
| Through the political action initiatives we undertake and promote. | 稀有
> 罕见病：遗传性 | 影响政策和立法
> 动员议员和政治领导人 | 100 | International | Regularly | 119078207611 |
| Legislation pertaining to patients living with a rare disease. | 稀有
> 罕见病：遗传性 | 影响政策和立法
> 倡导患者保护法案和权利 | 1,000 | National | Regularly | 119012112198 |
| Petitions have been submitted to the European Parliament — specifically to its Committee on Petitions, registered under number 1468/2024 — concerning the diagnosis and treatment of patients with coeliac disease in the EU. In addition, more than 17 resolutions have been advanced in the Parliament of Catalonia, all of which were adopted, alongside one Private Member's Bill (Proposición de Ley) and two Non-Legislative Motions (Proposiciones No de Ley) in the Congress of Deputies. Amendments have also been submitted to a number of legislative proposals, including the Universal Healthcare Access Bill, the Health Equity Bill, and the Medicines Bill, among others. | 胃肠道
> 乳糜泻 | 影响政策和立法
> 参与起草公共卫生法规 | 100,000 | National | Regularly | 119053766557 |
| Our objective is to advocate for the approval of all pancreatic cancer-related medicines in Spain. | 癌症
> 癌症：胰腺癌 | 影响政策和立法
> 解决医疗保健中的障碍/异常问题 | 1,000 | National | Rarely | 119012120290 |
| Nucleoside therapy for TK2d has recently received approval from the EMA [European Medicines Agency] and the FDA [Food and Drug Administration], so the next phase will be price regulation. | 稀有
> 罕见病：遗传性 | 定价与可负担性倡导
> 倡导公平的药品定价 | 100 | National | Regularly | 119070360428 |
| Reimbursement of biological treatments. | 呼吸系统
> 慢性阻塞性肺疾病（COPD） | 定价与可负担性倡导
> 倡导公平的药品定价 | 1,000 | National | Regularly | 119078128994 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | 慢性
> 慢性病（总体） | 定价与可负担性倡导
> 参与价格审查委员会谈判 | We do not communicate with patients directly | National | Regularly | 119052165521 |
| Nucleoside therapy for TK2d [Thymidine Kinase 2 deficiency] has recently received approval from the EMA [European Medicines Agency] and the FDA [Food and Drug Administration], so the next phase will be price regulation. | 稀有
> 罕见病：遗传性 | 定价与可负担性倡导
> 参与价格审查委员会谈判 | 100 | National | Regularly | 119070360428 |
| Meetings with the Directorate-General for the Common Benefits Package and Pharmacy. | 稀有
> 罕见病：代谢/溶酶体 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 100 | National | Rarely | 119022231157 |
| The priority is not so much determining the price, but securing reimbursement. | 呼吸系统
> 呼吸系统：大多数疾病 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 5,000 | National | Regularly | 119054105408 |
| … Reimbursement of biological therapies. | 呼吸系统
> 慢性阻塞性肺疾病（COPD） | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 1,000 | National | Regularly | 119078128994 |
| Our objective is to advocate for the approval of all pancreatic cancer-related medicines in Spain. | 癌症
> 癌症：胰腺癌 | 改善访问路径
> 促进公平获取药品/医疗保健 | 1,000 | National | Rarely | 119012120290 |
| We are engaged with the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency of Medicines and Medical Devices] to advocate for access to innovative treatments. | 患者权益倡导
> 患者权利 | 改善访问路径
> 促进公平获取药品/医疗保健 | We do not communicate with patients directly | National | Regularly | 119012238994 |
| We participate in the sampling of products entering public tender processes. | 内分泌
> 糖尿病（1型和2型） | 改善访问路径
> 促进公平获取药品/医疗保健 | 5,000 | Regional | Regularly | 119019803062 |
| We successfully halted the withdrawal of public reimbursement for SYSADOAs [Symptomatic Slow-Acting Drugs for Osteoarthritis], an effective and well-established treatment for osteoarthritis. | 骨骼
> 骨关节炎和骨质疏松症 | 改善访问路径
> 促进公平获取药品/医疗保健 | 5,000 | National | Regularly | 119022568142 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | 慢性
> 慢性病（总体） | 改善访问路径
> 促进公平获取药品/医疗保健 | We do not communicate with patients directly | National | Regularly | 119052165521 |
| Removal of the prior authorisation requirement for triple therapy [Doctors in Spain needed administrative approval from the National Health System to prescribe or fully reimburse a combined respiratory drug in a single inhaler.] | 呼吸系统
> 慢性阻塞性肺疾病（COPD） | 改善访问路径
> 促进公平获取药品/医疗保健 | 1,000 | National | Regularly | 119078128994 |
| Providing guidance from the patient perspective. | 稀有
> 罕见病：大多数类型 | 循证患者意见
> 利用患者洞察来指导决策 | 1,000 | National | Regularly | 119055416525 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | 患者权益倡导
> 患者权利 | 循证患者意见
> 利用患者洞察来指导决策 | 10,000 | National | Sometimes | 119073823192 |
| They consult us. | 神经系统
> 纤维肌痛 | 循证患者意见
> 利用患者洞察来指导决策 | Do not know | Local | Sometimes | 119075536668 |
| ... Advise from the patient's perspective. Influence through formal participation or institutional pressure. Contribute social evidence and patient experience. Contributing real-world evidence and patient experience. | 稀有
> 罕见病：大多数类型 | 循证患者意见
> 向监管机构提供真实世界证据（RWE） | 1,000 | National | Regularly | 119055416525 |
| ... Contributing real-world evidence and patient experience. | 稀有
> 罕见病：大多数类型 | 循证患者意见
> 利用患者故事和亲身经历叙述 | 1,000 | National | Regularly | 119055416525 |
| Associations of family members of patients with Alzheimer's disease [interacting with drug regulators]. | 神经退行性
> 阿尔茨海默症 | 循证患者意见
> 利用患者故事和亲身经历叙述 | We do not communicate with patients directly | Regional | Regularly | 119067801531 |
| POP [Plataforma de Organizaciones de Pacientes - Patients’ Organisations Platform] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access. | 慢性
> 慢性病（总体） | 循证患者意见
> 将证据和洞察转化为政策建议 | We do not communicate with patients directly | National | Regularly | 119052165521 |
| … We raise concerns on issues such as adverse drug reactions. | 老年人
> 老年人 | 诊断与药品配送
> 确保安全有效地使用药物 | We do not communicate with patients directly | National | Regularly | 119013803044 |
| By providing information on the indications for which administration of the orphan medicinal product is clearly necessary, as well as the circumstances in which alternative forms of healthcare provision may be expected or appropriate. | 稀有
> 冯·希佩尔-林道综合征 | 诊断与药品配送
> 确保安全有效地使用药物 | 100 | National | Rarely | 119046844450 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | 患者权益倡导
> 患者权利 | 诊断与药品配送
> 确保安全有效地使用药物 | 10,000 | National | Sometimes | 119073823192 |
| … We also issue practice recommendations for members of the ESGG [Sociedad Española de Geriatría y Gerontología – Spanish Society of Geriatrics and Gerontology]. | 老年人
> 老年人 | 诊断与药品配送
> 参与制定临床指南 | We do not communicate with patients directly | National | Regularly | 119013803044 |
| We provide advisory input to government authorities on specific matters and regulatory provisions relating to our area of practice — the older adult population. | 老年人
> 老年人 | 机构治理
> 确保在政府咨询机构中的代表性 | We do not communicate with patients directly | National | Regularly | 119013803044 |
| With public authorities. | 出血
> 血友病 | 机构治理
> 确保在政府咨询机构中的代表性 | 100 | Regional | Regularly | 119053275561 |
| Not directly through ACPA [Asociación Comarcal de Personas con Ansiedad - Regional Association of People with Anxiety], but through Rafael Martínez in his capacity as President of FEASAM [Federación de Asociaciones de Salud Mental de la Región de Murcia - Federation of Mental Health Associations of the Region of Murcia] and as a member of the POP [Patients’ Organisations Platform - Plataforma de Organizaciones de Pacientes] Patient Platform. | 心血管
> 心血管和心脏疾病 | 机构治理
> 确保在政府咨询机构中的代表性 | 100 | Local | No | 119053750627 |
| Providing guidance from the patient perspective. Exercising influence through formal participation or institutional advocacy. | 稀有
> 罕见病：大多数类型 | 机构治理
> 确保在政府咨询机构中的代表性 | 1,000 | National | Regularly | 119055416525 |
| We do not intervene in pricing decisions; however, we do represent and defend the interests of those we advocate for before the relevant public authorities. | 神经系统
> 多发性硬化症 | 机构治理
> 确保在政府咨询机构中的代表性 | 5,000 | Local | Regularly | 119064523376 |
| We represent the interests of patients, but we do not intervene in pricing decisions. | 神经系统
> 多发性硬化症 | 机构治理
> 确保在政府咨询机构中的代表性 | 10,000 | Regional | Rarely | 119065344758 |
| We are members of the Patient Committee of the Valencian Community. | HIV
> HIV | 机构治理
> 确保在政府咨询机构中的代表性 | 10,000 | Regional | No | 119072419533 |
| We are registered as an interest group with the Generalitat Valenciana in the REGIA [Registro de Grupos de Interés de la Administración de la Generalitat - Register of Interest Groups of the Administration of the Generalitat Valenciana] register under number 188. We participate on a bimonthly basis in strategic meetings held with both the Regional Ministry of Health and the Regional Ministry of Equality and Social Services. | HIV
> HIV | 机构治理
> 确保在政府咨询机构中的代表性 | 5,000 | Local | Regularly | 119072832940 |
| The relationship between Foro Español de Pacientes [Spanish Patients’ Forum] and the AEMPS [Agencia Española de Medicamentos y Productos Sanitarios – Spanish Agency for Medicines and Medical Devices] is primarily institutional, advisory, and collaborative in nature, with the aim of incorporating the patient perspective into medicines and medical devices policy in Spain.1. FEP participation in AEMPS bodies and committees. The FEP participates in a number of the Agency's advisory and technical bodies. For example, the President of the FEP, Andoni Lorenzo Garmendia, joined the AEMPS Committee for the Safety of Medicinal Products for Human Use. This involvement ensures that the patient voice and experience are taken into account in matters of safety and pharmacovigilance. In addition, the FEP participates in the monitoring and dissemination of IPT [Informes de Posicionamiento Terapéutico - Therapeutic Positioning Reports], prepared by the Agency for the evaluation of medicinal products. | 患者权益倡导
> 患者权利 | 机构治理
> 确保在政府咨询机构中的代表性 | 10,000 | National | Sometimes | 119073823192 |
| The organisation has held Public Interest status, as designated by the Spanish Ministry of the Interior, since 2008. | 神经系统
> 神经系统：大多数疾病 | 机构治理
> 维持公益或慈善实体的正式地位 | 1,000 | Local | Rarely | 119054524092 |
| We are registered as an interest group with the Generalitat Valenciana in the REGIA [Registro de Grupos de Interés de la Administración de la Generalitat - Register of Interest Groups of the Administration of the Generalitat Valenciana] register under number 188. | HIV
> HIV | 机构治理
> 维持公益或慈善实体的正式地位 | 5,000 | Local | Regularly | 119072832940 |
互动
行动与倡导
19 提及
